Source: Google NewsPublished on 2023-01-23
Related Articles:
- GB Sciences Granted US Patent for Cannabinoid-based Formulations for Parkinson’s May 7, 2020 GB Sciences has been granted a patent from the U.S. Patent and Trademark Office (USPTO) covering the use of its proprietary cannabinoid-containing complex mixtures for treating Parkinson’s disease, the company announced. GB Sciences is creating a pipeline of new medicines based on cannabinoids, the pharmacologically active compounds that give the cannabis plant its medical and recreational properties. The patent — number 10,653,640…
- CBG Dosing: A Complete Guide To CBG - The Island Now October 28, 2022 CBG Dosing: A Complete Guide To CBG The Island Now
- Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease March 10, 2022 Front Cell Neurosci. 2022 Feb 21;16:832854. doi: 10.3389/fncel.2022.832854. eCollection 2022.ABSTRACTParkinson's disease (PD) is a neurodegenerative disease usually caused by neuroinflammation, oxidative stress and other etiologies. Recent studies have found that the cannabinoid system present in the basal ganglia has a strong influence on the progression of PD. Altering the cannabinoid receptor activation status by modulating endogenous cannabinoid (eCB) levels can…
- Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease March 10, 2022 Front Cell Neurosci. 2022 Feb 21;16:832854. doi: 10.3389/fncel.2022.832854. eCollection 2022.ABSTRACTParkinson's disease (PD) is a neurodegenerative disease usually caused by neuroinflammation, oxidative stress and other etiologies. Recent studies have found that the cannabinoid system present in the basal ganglia has a strong influence on the progression of PD. Altering the cannabinoid receptor activation status by modulating endogenous cannabinoid (eCB) levels can…
- Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease March 10, 2022 Front Cell Neurosci. 2022 Feb 21;16:832854. doi: 10.3389/fncel.2022.832854. eCollection 2022.ABSTRACTParkinson's disease (PD) is a neurodegenerative disease usually caused by neuroinflammation, oxidative stress and other etiologies. Recent studies have found that the cannabinoid system present in the basal ganglia has a strong influence on the progression of PD. Altering the cannabinoid receptor activation status by modulating endogenous cannabinoid (eCB) levels can…
- Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease March 10, 2022 Front Cell Neurosci. 2022 Feb 21;16:832854. doi: 10.3389/fncel.2022.832854. eCollection 2022.ABSTRACTParkinson's disease (PD) is a neurodegenerative disease usually caused by neuroinflammation, oxidative stress and other etiologies. Recent studies have found that the cannabinoid system present in the basal ganglia has a strong influence on the progression of PD. Altering the cannabinoid receptor activation status by modulating endogenous cannabinoid (eCB) levels can…
- Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease March 10, 2022 Front Cell Neurosci. 2022 Feb 21;16:832854. doi: 10.3389/fncel.2022.832854. eCollection 2022.ABSTRACTParkinson's disease (PD) is a neurodegenerative disease usually caused by neuroinflammation, oxidative stress and other etiologies. Recent studies have found that the cannabinoid system present in the basal ganglia has a strong influence on the progression of PD. Altering the cannabinoid receptor activation status by modulating endogenous cannabinoid (eCB) levels can…
- Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease March 10, 2022 Front Cell Neurosci. 2022 Feb 21;16:832854. doi: 10.3389/fncel.2022.832854. eCollection 2022.ABSTRACTParkinson's disease (PD) is a neurodegenerative disease usually caused by neuroinflammation, oxidative stress and other etiologies. Recent studies have found that the cannabinoid system present in the basal ganglia has a strong influence on the progression of PD. Altering the cannabinoid receptor activation status by modulating endogenous cannabinoid (eCB) levels can…
- Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease March 10, 2022 Front Cell Neurosci. 2022 Feb 21;16:832854. doi: 10.3389/fncel.2022.832854. eCollection 2022.ABSTRACTParkinson's disease (PD) is a neurodegenerative disease usually caused by neuroinflammation, oxidative stress and other etiologies. Recent studies have found that the cannabinoid system present in the basal ganglia has a strong influence on the progression of PD. Altering the cannabinoid receptor activation status by modulating endogenous cannabinoid (eCB) levels can…
- Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice. December 19, 2020 Related ArticlesNeuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice. Mol Cell Neurosci. 2020 Dec 15;:103583 Authors: Burgaz S, García C, Gómez-Cañas M, Navarrete C, García-Martín A, Rolland A, Del Río C, Casarejos MJ, Muñoz E, Gonzalo-Consuegra C, Muñoz E, Fernández-Ruiz J Abstract The quinone derivative of the non-psychotropic cannabinoid…
- Cannabigerol (CBG): What is it, and How Should I Use it? | Westword - Westword February 16, 2021 Cannabigerol (CBG): What is it, and How Should I Use it? | Westword Westword
- “I want to break the silence and stigma associated with Parkinson’s disease” October 21, 2021 Christine Jeyachandran, a Parkinson’s blogger and filmmaker based in Peru, discusses how her own Parkinson’s diagnosis inspired her to make the short documentary film, ‘Would you sell your house to save your mother?’ Tell us about your experience of Parkinson’s disease. When I was diagnosed, almost eight years ago in Peru, I was just 37 years old. I asked the…
- TODAY: Gb Sciences' President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containin - Benzinga May 23, 2022 TODAY: Gb Sciences' President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containin Benzinga
- Inhibikase Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022 - Benzinga - Benzinga May 9, 2022 Inhibikase Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022 - Benzinga Benzinga
- Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021 - Benzinga - Benzinga July 4, 2021 Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021 - Benzinga Benzinga
- Global Parkinson's Disease Treatment Market to Reach $7.2 Billion by 2027 - Benzinga - Benzinga September 9, 2021 Global Parkinson's Disease Treatment Market to Reach $7.2 Billion by 2027 - Benzinga Benzinga
- Asceneuron to Provide Update on O-GlcNAcase Pipeline at Upcoming Conferences - Benzinga - Benzinga September 30, 2021 Asceneuron to Provide Update on O-GlcNAcase Pipeline at Upcoming Conferences - Benzinga Benzinga
- Unite to Fight V - Boulder's Only Amateur Charity Boxing Tournament is Back! - Benzinga - Benzinga November 3, 2021 Unite to Fight V - Boulder's Only Amateur Charity Boxing Tournament is Back! - Benzinga Benzinga
- DIAN-TU selects lecanemab for clinical trial for dominantly inherited Alzheimer's disease - Benzinga - Benzinga November 8, 2021 DIAN-TU selects lecanemab for clinical trial for dominantly inherited Alzheimer's disease - Benzinga Benzinga
- Yumanity Therapeutics Stock Plunges After Parkinson's Trial Data - Benzinga - Benzinga November 10, 2021 Yumanity Therapeutics Stock Plunges After Parkinson's Trial Data - Benzinga Benzinga
- Neurodegenerative Disorder Therapeutics Global Market Report 2021 - Benzinga - Benzinga December 29, 2021 Neurodegenerative Disorder Therapeutics Global Market Report 2021 - Benzinga Benzinga
- Parkinson's Disease Pipeline Offers Promising New Options for Treatment | DelveInsight - Benzinga - Benzinga January 18, 2022 Parkinson's Disease Pipeline Offers Promising New Options for Treatment | DelveInsight - Benzinga Benzinga